During the past decade, Centro Hospitalar do Algarve - Hospital de Portimao conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Hospitalar do Algarve - Hospital de Portimao" #1 sponsor was "Shire" with 5 trials, followed by "Centro Hospitalar Universitario do Algarve" with 2 trials sponsored, "Galapagos NV" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Hospitalar do Algarve - Hospital de Portimao" #1 collaborator was "Gilead Sciences" with 2 trials as a collaborator, "Universidade do Algarve" with 2 trials as a collaborator, "Universidade do Porto" with 2 trials as a collaborator, "Center for Health Technology and Services Research" with 1 trials as a collaborator and "Linde Health Care" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Centro Hospitalar do Algarve - Hospital de Portimao" are "Crohn's Disease" (6 trials), "Ulcerative Colitis" (3 trials), "Chronic Rhinosinusitis" (2 trials), "Nasal Polyps" (2 trials) and "Anxiety Depression" (1 trials). Many other conditions were trialed in "Centro Hospitalar do Algarve - Hospital de Portimao" in a lesser frequency.

Most popular intervention types in "Centro Hospitalar do Algarve - Hospital de Portimao" are "Drug" (11 trials), "Other" (6 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Ontamalimab" (4 trials), "Filgotinib" (2 trials), "Omalizumab" (2 trials) and "Ustekinumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centro Hospitalar do Algarve - Hospital de Portimao" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Centro Hospitalar do Algarve - Hospital de Portimao". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in Centro Hospitalar do Algarve - Hospital de Portimao, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Hospitalar do Algarve - Hospital de Portimao, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".